论文部分内容阅读
目的探讨替吉奥联合奥沙利铂方案(SOX方案)在进展期胃癌一线化学疗法(化疗)中的疗效及毒副反应。方法选取2012年3月-2013年4月广西医科大学第一附属医院57例进展期胃癌患者给予SOX方案化疗,奥沙利铂130 mg/m2静脉滴注,第1天用药;替吉奥按体表面积决定用量(<1.25 m2:40 mg,2次/d;1.25~1.50 m2:50 mg,2次/d;>1.50 m2:60 mg,2次/d)口服,第1~14天用药;21 d为1个周期,每2个周期评价疗效。结果 SOX方案客观有效率为52.6%,疾病控制率为84.2%,中位疾病进展时间为5.8个月,中位总生存时间为13.5个月。3~4级血液学不良反应主要是中性粒细胞减少(12.3%)和血小板减少(12.3%);3~4级非血液学不良反应主要有呕吐、乏力及周围神经毒性。临床收益率为71.9%(41/57)。结论 SOX方案一线治疗进展期胃癌疗效确切,毒副反应低,耐受性良好,值得推广应用。
Objective To investigate the efficacy and toxicities of the combination of tioguanide and oxaliplatin (SOX) in first-line chemotherapy of advanced gastric cancer (chemotherapy). Methods From March 2012 to April 2013, 57 patients with advanced gastric cancer in the First Affiliated Hospital of Guangxi Medical University were given SOX regimen and oxaliplatin 130 mg / m 2 intravenously on the first day, Body surface area is determined by the amount of (<1.25 m2: 40 mg, 2 times /d;1.25 ~ 1.50 m2: 50 mg, 2 times /d;>1.50 m2: 60 mg, 2 times / d) ; 21 d for a cycle, evaluation of the efficacy of every 2 cycles. Results Objectively effective rate of SOX regimen was 52.6%, disease control rate was 84.2%, median disease progression time was 5.8 months, and median overall survival time was 13.5 months. Grade 3 to 4 hematologic adverse reactions were mainly neutropenia (12.3%) and thrombocytopenia (12.3%); grade 3 to 4 non-hematologic adverse reactions were mainly vomiting, fatigue and peripheral neurotoxicity. The clinical rate of return was 71.9% (41/57). Conclusion The first-line treatment of advanced gastric cancer with SOX regimen has definite curative effect, low toxicity and good tolerability, which is worth popularizing and applying.